Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions

INTRODUCTION: There is an urgent need to develop new drugs to treat malaria due to increasing resistance to first-line therapeutics targeting the causative organism, Plasmodium falciparum (P. falciparum). One drug candidate is DM1157, a small molecule that inhibits the formation of hemozoin, which p...

Descripción completa

Detalles Bibliográficos
Autores principales: Balevic, Stephen J., Raja, Shruti M., Randell, Rachel, Deye, Gregory A., Conrad, Thomas, Nakamura, Aya, Peyton, David H., Shotwell, Sandra, Liebman, Katherine, Cohen-Wolkowiez, Michael, Guptill, Jeffrey T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960550/
https://www.ncbi.nlm.nih.gov/pubmed/35184256
http://dx.doi.org/10.1007/s40121-022-00605-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960550/
https://www.ncbi.nlm.nih.gov/pubmed/35184256
http://dx.doi.org/10.1007/s40121-022-00605-z

Ejemplares similares